In-Depth Study on Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. 

Complete report available @ Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017

The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Chronic Lymphocytic Leukemia (CLL), Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Amgen Inc ArQule Inc Astellas Pharma Inc AstraZeneca Plc Blueprint Medicines Corp Bristol-Myers Squibb Company Eisai Co Ltd Eli Lilly and Company Genosco Inc H3 Biomedicine Inc Incyte Corp Ionis Pharmaceuticals Inc Johnson & Johnson NGM Biopharmaceuticals Inc Novartis AG Principia Biopharma Inc Tasly Pharmaceutical Group Co Ltd Vichem Chemie Research Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###